Tumor necrosis factor and human acute leukemia.

abstract：:Ibrutinib is a first-in-class small molecule inhibitor that has shown remarkable efficacy in the treatment of CLL. Current guidelines recommend lifelong administration at a fixed daily dose of 420 mg. Data from real-world studies indicate up to 17.5% of patients discontinue ibrutinib due to toxicity. Hypothetically, j...

journal_title：Leukemia & lymphoma

authors： Akhtar OS,Attwood K,Lund I,Hare R,Hernandez-Ilizaliturri FJ,Torka P

更新日期：2019-07-01 00:00:00

abstract：:Forty patients, with mainly poor risk haematological malignancies, were given the new regimen FLAG, comprising fludarabine, arabinosyl cytosine and G-CSF. Twenty four patients had acute myeloid leukaemia (AML), 8 patients myelodysplastic syndrome (MDS) and a further 8 patients had a variety of other haematological mal...

journal_title：Leukemia & lymphoma

authors： Nokes TJ,Johnson S,Harvey D,Goldstone AH

更新日期：1997-09-01 00:00:00

abstract：:The purpose of this study was to evaluate the role of 18F-fluorodeoxyglucose ((18)F-FDG) positron emission tomography-computed tomography (PET-CT) in detecting relapse in patients with primary gastric lymphoma (PGL) post-treatment. Data of 39 previously treated patients with PGL (age: 50.3 ± 13.8 years; male: 24) who ...

journal_title：Leukemia & lymphoma

authors： Sharma P,Suman SK,Singh H,Sharma A,Bal C,Malhotra A,Kumar R

更新日期：2013-05-01 00:00:00

abstract：:There is insufficient information on the characteristics of chronic lymphocytic leukemia (CLL) in Latin American patients. Immunoglobulin variable-region heavy-chain (IGVH) gene usage and mutation status and prognostic factors were investigated in patients resident in Venezuela. The most frequently used IGVH family ge...

journal_title：Leukemia & lymphoma

authors： Marquez ME,Deglesne PA,Lopez JL,Da Costa O,Borrego M,Hernández M,Muller A,Ajchenbaum-Cymbalista F,Romano E

更新日期：2012-02-01 00:00:00

abstract：:B-cell chronic lymphocytic leukemia (CLL) is a clonal B cell malignancy of morphologically mature, functionally immature B cells. B-cell CLL cells are known to be resistant to killing by anticancer and other agents. This resistance is associated with alterations in apoptosis and cell cycle regulated genes. In our earl...

journal_title：Leukemia & lymphoma

authors： Wang P,Pavletic ZS,Joshi SS

更新日期：2002-09-01 00:00:00

abstract：:We performed three different studies to obtain additional data on the biological and prognostic role of vascular endothelial growth factor C (VEGFC) in classical Hodgkin lymphoma (cHL): (1) serum VEGFC levels were measured by enzyme-linked immunosorbent assay in 80 patients; (2) immunohistochemical VEGFC expression in...

journal_title：Leukemia & lymphoma

authors： Rueda A,Olmos D,Vicioso L,Quero C,Gallego E,Pajares-Hachero BI,Mendiola M,Casanova M,Álvarez M,Provencio M,Alba E

更新日期：2015-05-01 00:00:00

abstract：:To identify epigenetically silenced miRNAs and to investigate their influences on predictive target oncogenes in extranodal natural killer/T-cell lymphoma (NKTCL). Decitabine treatment was performed to evaluate methylated miRNAs in NKTCL cells. The relationship between a given miRNA and its target mRNA was validated u...

journal_title：Leukemia & lymphoma

authors： Go H,Jang JY,Kim CW,Huh J,Kim PJ,Jeon YK

更新日期：2020-01-01 00:00:00

abstract：:Abstract ATM gene alteration is a frequent event in pathogenesis of chronic lymphocytic leukemia (CLL) and occurs as monoallelic loss in the form of 11q23 deletion, with and without mutation in the remaining ATM allele. ATM is a principal DNA damage response gene and biallelic ATM alterations lead to ATM functional lo...

journal_title：Leukemia & lymphoma

authors： Stankovic T,Skowronska A

更新日期：2014-06-01 00:00:00

abstract：:Anti-B4-blocked ricin (anti-B4-bR) is a potent immunotoxin directed against the CD19 antigen. Previous phase I and II studies suggested a possible role for anti-B4-bR as consolidation after high-dose chemotherapy and autologous stem cell transplant. Cancer and Leukemia Group B (CALGB) 9254 is a phase III study which r...

journal_title：Leukemia & lymphoma

authors： Furman RR,Grossbard ML,Johnson JL,Pecora AL,Cassileth PA,Jung SH,Peterson BA,Nadler LM,Freedman A,Bayer RL,Bartlett NL,Hurd DD,Cheson BD,Cancer Leukemia Group B.,Eastern Cooperative Oncology Group.

更新日期：2011-04-01 00:00:00

abstract：:Abstract Reconstitution, engraftment kinetics and tumor cell clearance were analyzed after reduced intensity conditioning hematopoietic cell transplant (RIC-HCT) in patients with chronic lymphocytic leukemia (CLL). Patients were transplanted from unrelated (n = 40) or related (n = 10) donors after fludarabine and 2 Gy...

journal_title：Leukemia & lymphoma

authors： Hebenstreit K,Iacobelli S,Leiblein S,Eisfeld AK,Pfrepper C,Heyn S,Vucinic V,Franke GN,Krahl R,Fricke S,Becker C,Pönisch W,Behre G,Niederwieser D,Lange T

更新日期：2014-06-01 00:00:00

abstract：:Analysis of different ribonucleotide reductase inhibitors to modulate arabinosylcytosine (ara-C) metabolism suggested that pretreatment with arabinosyl-2-fluoroadenine (F-ara-A) significantly potentiated the rate of ara-CTP (5'-triphosphate of ara-C) accumulation in both quiescent lymphocytes (p = 0.046) and in cyclin...

journal_title：Leukemia & lymphoma

authors： Gandhi V,Estey E,Keating MJ,Plunkett W

更新日期：1993-01-01 00:00:00

abstract：:The adenosine deaminase inhibitor 2'-deoxycoformycin (dCF) significantly inhibits the proliferation of leukemia and lymphoma cells in the presence of either 2'-deoxyadenosine (dAdo) or its analog adenine arabinoside (araA). The concentration of dCF required to induce apoptosis of monocytoid leukemia cells is much lowe...

journal_title：Leukemia & lymphoma

authors： Honma Y

更新日期：2001-09-01 00:00:00

abstract：:The increased number of CD5+ B-cells in some human autoimmune diseases, the frequent commitment of CD5+ B-cells to the production of natural autoantibodies, and the apparent involvement of these cells in the pathogenesis of the autoimmune hemolytic anemia (AIHA) in certain mouse models suggests a causal relationship b...

journal_title：Leukemia & lymphoma

authors： Efremov DG,Ivanovski M,Burrone OR

更新日期：1998-01-01 00:00:00

abstract：:Adhesion molecules such as CD2 and its ligand CD58 (LFA-3), as well as CD11a/18 (LFA-1) and CD54 (ICAM-1) regulate not only cell to cell attachment but also participate in lymphocyte activation, recirculation, and effector function including cytolytic activity towards tumor cells. We have investigated the role of CD2/...

journal_title：Leukemia & lymphoma

authors： Schirren CA,Völpel H,Hoffmann JC,Henning SW,Qiao L,Autschbach F,Dengler TJ,Döhner H,Meuer SC

更新日期：1993-05-01 00:00:00

abstract：:There is little evidence about whether additional risk stratification for adult patients with acute lymphoblastic leukemia age 65 and older is warranted. Using the Surveillance, Epidemiology, and End Results data linked to Medicare claims, we examined the effects of age, comorbid conditions, and mobility limitations o...

journal_title：Leukemia & lymphoma

authors： Danese MD,Katz A,Cetin K,Chia V,Gleeson ML,Kelsh M,Griffiths RI

更新日期：2019-08-01 00:00:00

abstract：:The MTT-based assay relies upon the cellular reduction of tetrazolium salts to their intensely colored formazans. The test is easy to perform in hematological malignancies and is adaptable for high throughput of samples, although there are some minor limitations in its application resulting from metabolic interference...

journal_title：Leukemia & lymphoma

authors： Hayon T,Dvilansky A,Shpilberg O,Nathan I

更新日期：2003-11-01 00:00:00

abstract：:To clarify the significance of post-transplant serum ferritin (SF), we retrospectively assessed pre- and post-transplant SF. Among 256 patients undergoing allogeneic stem cell transplant (SCT) for hematologic malignancies between 2000 and 2011, those who had relapsed within 1 year were excluded, and 110 patients survi...

journal_title：Leukemia & lymphoma

authors： Tachibana T,Tanaka M,Numata A,Matsumoto K,Tomita N,Fujimaki K,Taguchi J,Sakai R,Fujita H,Fujisawa S,Maruta A,Ishigatsubo Y,Kanamori H

更新日期：2014-06-01 00:00:00

abstract：:HMGB1 is a high mobility group protein that can act either as a DNA binding protein or extracellularly as a cytokine-like danger signal. Extracellular HMGB1, either actively secreted or passively released by necrotic cells, is linked to inflammation and cancer. Herein, the results of a study to quantify the expression...

journal_title：Leukemia & lymphoma

authors： Meyer A,Staratschek-Jox A,Springwald A,Wenk H,Wolf J,Wickenhauser C,Bullerdiek J

更新日期：2008-06-01 00:00:00

abstract：:Despite progress in AML therapy, most patients eventually relapse, even the ones with normal or favorable karyotype. Since survival is poor once relapse occurs, new genetic tools above karyotype at diagnosis are needed to predict leukemia free survival. Recently, Flt3/ITD has been reported as an independent marker for...

journal_title：Leukemia & lymphoma

authors： Ciolli S,Vannucchi AM,Leoni F,Nozzoli C,Longo G,Salati A,Pancrazzi A,Bianchi L,Gigli F,Bosi A

更新日期：2004-01-01 00:00:00

abstract：:The therapeutic landscape for chronic lymphocytic leukemia has significantly evolved in recent years as our understanding of the biology of this disease has advanced. Chemoimmunotherapy has been the standard frontline treatment for patients of all age groups with chronic lymphocytic leukemia over the last decade. B-ce...

journal_title：Leukemia & lymphoma

authors： Bhat SA,Woyach JA

更新日期：2020-03-01 00:00:00

abstract：:The addition of arsenic trioxide (ATO) to frontline therapy of acute promyelocytic leukemia (APL) has been shown to result in significant improvements in disease-free survival (DFS). FLT3 mutations are frequently observed in APL, but its prognostic significance remains unclear. We analyzed 245 newly diagnosed adult pa...

journal_title：Leukemia & lymphoma

authors： Poiré X,Moser BK,Gallagher RE,Laumann K,Bloomfield CD,Powell BL,Koval G,Gulati K,Holowka N,Larson RA,Tallman MS,Appelbaum FR,Sher D,Willman C,Paietta E,Stock W

更新日期：2014-07-01 00:00:00

abstract：:Chronic myelogenous leukaemia (CML) is one of the most intensively studied human malignancies. It has been the focus of major efforts to develop potent drugs for several decades, but until recently cure rates remained low. A breakthrough in CML therapy was very likely accomplished with the clinical introduction of STI...

journal_title：Leukemia & lymphoma

authors： Feller SM,Tuchscherer G,Voss J

更新日期：2003-03-01 00:00:00

abstract：:Angiogenesis is a necessary step in solid tumor progression (growth, invasion and metastasis) with which it correlates and is indicative of an unfavourable prognosis. We observed bone marrow angiogenesis in patients with active multiple myeloma (MM), though not in patients with non-active MM nor with monoclonal gammop...

journal_title：Leukemia & lymphoma

authors： Vacca A,Ribatti D,Roncali L,Dammacco F

更新日期：1995-12-01 00:00:00

abstract：:Binding of Fas ligand (FasL) or an agonistic anti-Fas receptor (Fas/CD95) antibody induces apoptosis in Fas-bearing target cells. The involvement of Fas/FasL pathway has been investigated in human acute myelogenous leukemia (AML) cells. Fas/CD95 is expressed on a majority of AML cells, although the intensity of expres...

journal_title：Leukemia & lymphoma

authors： Komada Y,Sakurai M

更新日期：1997-03-01 00:00:00

abstract：:The rearrangement of the immunoglobulin genes (IG) provides a large diversity of B-cell receptors conformations and allows the immune system to respond differently to foreign antigens. In chronic lymphocytic leukemia (CLL), there are a restricted number of stereotyped B-cell receptors rearranged by the tumor B-cells b...

journal_title：Leukemia & lymphoma

authors： Tobin G

更新日期：2007-06-01 00:00:00

abstract：:We investigated the antitumor effect of a short-chain polysaccharide (PS) extracted from porcine cartilage both in L1210 leukemic cells in vitro and in mice bearing L1210 ascites tumors. Our results show that treatment with PS resulted in a significant (P < 0.01) inhibition of cell proliferation and caused apoptotic d...

journal_title：Leukemia & lymphoma

authors： Liu A,Yang N,Song W,Cao D,Wang W

更新日期：2009-06-01 00:00:00

abstract：:Monoclonal IgM-related neuropathies constitute a heterogeneous group of disorders, which are generally poorly responsive to treatment. Rituximab, a chimeric monoclonal antibody against the CD20 molecule, has been used with success in patients with neuropathy and monoclonal IgM with anti-MAG or anti-GM1 ganglioside act...

journal_title：Leukemia & lymphoma

authors： Kilidireas C,Anagnostopoulos A,Karandreas N,Mouselimi L,Dimopoulos MA

更新日期：2006-05-01 00:00:00

abstract：:Abstract Acute graft-versus-host disease (GVHD) has compromised and continues to compromise the benefits associated with allogeneic hematopoietic cell transplant to cure malignant and non-malignant diseases. Pharmacologic interventions to prevent GVHD have emerged as a major objective of research in the immunology and...

journal_title：Leukemia & lymphoma

authors： Ram R,Storb R

更新日期：2013-08-01 00:00:00

abstract：:In developed nations, Hodgkin lymphoma (HL) is rare in <5-year olds and represent a minority in developing countries. Little is reported about the biology and behavior of these very young patients compared with older children. 18.75% of our pediatric HL patients (0 - 14 years) were <5 years at diagnosis. This group ha...

journal_title：Leukemia & lymphoma

authors： Belgaumi A,Al-Kofide A,Joseph N,Jamil-Malik R,Khafaga Y,Sabbah R

更新日期：2008-05-01 00:00:00

abstract：:When lymph node biopsies of lymphocytic neoplasms are studied with subtle morphological and immunohistochemical methods meaningful information is obtained, that is not only of theoretical value, but which also relates to the clinical behavior ("leukemia," paraproteinemia, prognosis). Such an analysis allows us to diff...

journal_title：Leukemia & lymphoma

authors： Lennert K,Tamm I,Wacker HH

更新日期：1991-01-01 00:00:00